Pharmaceutical company Humanetics has developed a proprietary compound designed to protect healthy tissue from the damaging effects of radiation, such as from routine CT scans and x-rays.
Preclinical studies conducted through research grants from the U.S. National Institutes of Health and the U.S. Department of Health and Human Services show that the compound, BIO 300, protects healthy lung tissue from the harmful effects of ionizing radiation exposure, according to the company.
Humanetics plans to begin a clinical trial in the second quarter of 2015 to evaluate BIO 300's ability to reduce the side effects to normal tissue from chemotherapy and radiation associated with lung cancer treatment.
